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Abstract
OBJECTIVE: To assess the efficacy of Traditional
Chinese Medicine (TCM) on constipation-predomi-
nant irritable bowel syndrome by focusing on the
liver.
METHODS: Databases (domestic and foreign) were
searched with the key words "irritable bowel syn-
drome", "constipation", and "Chinese medicine"; the
relevant articles were retrieved and evaluated. Cure
rate, "remarkable efficacy", recurrence rate and the
incidence of adverse reactions were the outcome
indicators. Review Manager ver 5.1 was used for
this meta-analysis, and funnel plots used to detect
publication bias.
RESULTS: Nineteen randomized controlled trials
were included and 1510 patients involved. The
treatment guided by TCM based on the liver was su-
perior to Western Medicine [odds ratio (OR) =2.46,
95% confidence interval (CI) 1.80, 3.35)], cure rate
[OR=2.61, 95% CI (1.93, 3.52)], remarkable efficacy
[OR=2.68, 95% CI (1.82, 3.95)], recurrence rate [OR=
0.19, 95% CI (0.12, 0.29)] and the incidence of ad-
verse reactions [OR=0.24, 95% CI (0.09, 0.65)]. How-
ever, funnel plots showed publication bias.
CONCLUSION: Compared with Western Medicine,
the treatment of IBS-C based on the liver is signifi-
cantly better but the results must be treated with
caution because publication bias was recorded.
© 2013 JTCM. All rights reserved.
Key words: Meta-analysis; Medicine, Chinese tradi-
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INTRODUCTION
In recent years, the incidence of irritable bowel syn-
drome (IBS) in Western and Asian countries has been
increasing, and has greatly affected people's quality of
life (QoL).1,2 Medical treatment is focused mainly on
regulation of intestinal transit and visceral sensation,
anxiolytics, and antidepressants. However, the "ideal"
therapy for IBS has not yet been formulated.3
Traditional Chinese Medicine (TCM) may have some
advantages in the treatment of IBS. Some systematic re-
views have reported that TCM has effects against con-
stipation-predominant irritable bowel syndrome
(IBS-C) and diarrhea predominant irritable bowel syn-
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drome (IBS-D).4,5 In terms of TCM theory, Zhou et al 6
stated that the pathogenesis of IBS-C could be attribut-
ed to "deficiency" and "stagnation". Stagnation of liver
Qi was considered to be the key factor and spleen defi-
ciency another factor in the pathogenesis of IBS-C.
Chen et al 7 categorized patients with IBS into three
syndromes: stagnation of liver Qi; stagnation of liver
Qi and spleen deficiency; and deficiency of liver Qi
and Yang. They found that the syndrome of stagnation
of liver Qi is more common in IBS-C or IBS with con-
stipation and diarrhea alternating (IBS-A). The syn-
drome of stagnation of liver Qi and spleen deficiency is
more common in IBS-D or IBS-A. The syndrome of
deficiency of liver Qi and Yang is seen only in IBS-D.
Thus, dispersing stagnated liver Qi and regulating
Qi-flow should be the key objectives when investigat-
ing the effect of treating IBS-C with TCM focusing on
the liver.
METHODS
Chinese Biomedical Literature (CBM) database, China
National Knowledge Infrastructure (CNKI) database
and Pubmed were searched with the key words "irrita-
ble bowel syndrome" and "constipation" and "Chinese
medicine". Five criteria were used. The first was that
randomized controlled clinical trials (blinded or un-
blinded) were selected. The second criterion was that
patients met the diagnostic criteria (international or na-
tional) for IBS-C. The third was that the TCM inter-
vention involved Sini powder, Chaihushugan powder,
Tongxieyao Fang, Xiaoyao powder as the basic recipes,
or that prescribed recipes (including herbs having the
effect of dispersing stagnated liver Qi and regulating
Qi-flowing, e.g., Chaihu (Radix Bupleuri Chinensis),
Baishao (Radix Paeoniae Alba), Zhiqiao (Fructus Auran-
tii Submaturus), Chenpi (Pericarpium Citri Reticulatae)
or Xiangfu (Rhizoma Cyperi) were the primary or ad-
junct medicine. The fourth criterion was that the study
included a comparison with Western Medicines, in-
cluding intestinal prokinetic drugs, serotoninergic
agents, antidepressants and anxiolytics. The final crite-
rion was that the article was published between 1979
and October 2011.
The primary outcome was cure rate (main symptoms
and primary symptoms), efficacy (main symptoms and
primary symptoms) and other outcomes. The second-
ary outcomes were recurrence rate, symptom improve-
ment, and safety (side effects and incidence of adverse
reactions). Two reviewers assessed the quality of an in-
dividual study independently. If there was disagree-
ment, the two reviewers discussed it to reach a consen-
sus. If agreement was still not met, they sought help
from a third party. The assessment was done following
the "Risk of Bias" table (Figure 1), recommended in
Cochrane Handbook 5.0. Studies were evaluated using
the following items: (a) random sequence generation
(selection bias); (b) allocation concealment (selection
bias); (c) blinding of participants and personnel (per-
formance bias); (d) blinding of outcome assessment
(detection bias); (e) incomplete outcome data (attrition
bias); (f ) selective reporting (reporting bias); and (g)
other types of bias.
The data extracted (Table 1) comprised general infor-
mation regarding the study (first author, year of publi-
cation); nature of the study; general information about
the participants; diagnostic criteria for IBS-C; sample
size; intervention of the treatment group and control
group; indicators of primary outcomes; indicators of
secondary outcomes; course of treatment; and post-in-
tervention indicators of improvement of symptoms. Re-
view Manager (RevMan) (vers 5.1, Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collabora-
tion, 2011) software was used for analyses. If the out-
come of the heterogeneity test was not significant, a
meta-analysis was done, and a fixed or random-effects
model selected. Funnel plot analyses were undertaken
to detect publication bias.
RESULTS
A total of 344 articles (337 in Chinese and 7 in Eng-
lish) were found. By excluding non-randomized con-
trolled trials and duplicates, 116 articles (115 in Chi-
nese and 1 in English) were available. After further re-
view, we excluded trials that were not conducted with
TCM treatment based on the liver, and those in which
the subjects were not constipated. Then, 19 articles (18
inChinese and 1 inEnglish)were eligible for the analysis.
Among them, the biggest sample size was 129 and the
smallest 47 (mean, 79) and 1510 subjects were in-
volved. In 3 of the 19 studies, IBS-C was diagnosed
with the criteria stated in Practical Medicine,8-10 1 with
the IBS criteria colloquium on chronic diarrhea of Chi-
na formulated in the 1986,11 1 with Rome criteria,12 12
with Rome II13-24 and 2 with Rome III.25,26
TCM interventions in the 19 articles were mainly Chi-
nese herbal compounds. None of them used a single
herb or Chinese patented medicine for treatment. All
19 studies used TCM formulas with the effect of dis-
persing stagnated liver Qi and regulating Qi-flow. West-
ern Medicine interventions in the 19 studies were: (a)
prokinetic drugs (15 articles): 11 were compared with
cisapride,8,10-12,14-18,22,24 2 with trimebutine,9,23 1 with mo-
sapride21 and 1 with tegaserod;19 and (b) laxatives (4 ar-
ticles): all were compared with polyethylene glycol.13,20,25,26
Details of the randomized controlled trials included in
the analysis are shown in Table 1.
Of the 19 studies, 12 used cure rate (recent cure rate)
as the best outcome indicator11,13,14,16,17,19-23,25,26 and 7 used
"remarkable efficacy".8-10,12,15,18,24 Nine studies showed
that symptoms improved, but only 2 of them provided
mean values and variance of the integration difference
before and after treatment.19,25 Eight of the studies re-
ported the recurrence rate 3-6 months after the trial.8,10,
12,15,16,22,24,26 Six studies reported on the incidence of ad-
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verse reactions,13-15,22,23,26 2 of which reported no adverse
reactions.22,23 Three studies used health-related QoL
scores as well as the plasma level of somatostatin and
vasoactive intestinal peptide as outcome indicators.22,23
Upon consideration of the combined effect as well as
the statistical effect, then cure rate, remarkable efficacy,
general efficacy, recurrence rate and incidence of ad-
verse reactions were used as outcome indicators.
All 19 articles mentioned "randomization" and report-
ed the baseline characteristics and statistical differences
with regard to sex, age and disease course between the
treatment group and control group, but only 2 of the
studies mentioned the specific method of randomiza-
tion. Only 1 of the articles reported patient withdrawal
from the study and its cause. None of the articles men-
tioned allocation concealment or blinding. In sum, the
studies were not rigorous, and the overall bias was
quite considerable (Figure 1).
Efficacy evaluation
In 1510 patients, 840 received TCM and 670 were
treated with Western Medicine. The outcomes showed
that the efficacy of TCM treatment based on the liver
was significantly higher than that of Western Medicine
(Figure 2).
Of the 12 studies that used cure rate as the best indica-
tor of outcome, 1057 patients (595 received TCM
treatment and 462 were treated with Western Medi-
cine) were involved. The outcomes showed that the
cure rate and remarkable efficacy of TCM treatment
based on the liver were significantly higher than those
of Western Medicine (Figures 3, 4).
In the 8 studies that focused on recurrence rate, 556 pa-
tients (331 received TCM medication and 225 were
treated with Western Medicine) were involved. The
outcomes showed that the recurrence rate of TCM
treatment based on the liver was significantly lower
than that of Western Medicine (Figure 5).
In the 6 studies that focused on adverse reactions, 578
patients (330 received TCM treatment and 248 were
treated with Western Medicine) were involved. The
outcomes indicated that the incidence of adverse reac-
tions of TCM treatment based on the liver was signifi-
cantly lower than that of Western Medicine (Figure 6).
Figures 7-11 display the outcomes of funnel plots. The
analyses showed that there was a possible publication
bias inherited from the studies.
DISCUSSION
Treatment based on the liver is an important method
for IBS intervention in TCM. In terms of TCM theo-
ry, the liver controls conveyance and dispersion, and
stores blood. "What governs conveyance and disper-
sion is the liver".27 If Qi movement is obstructed, the
stomach and spleen Qi would not function optimally,
which would cause abdominal pain, imbalance of fluid
diffusion, dryness of the bowel, and disorder of bowel
function. These effects would lead to abdominal pain
and constipation. Henningsen and colleagues28 re-
viewed articles on Medline and PsycLIT/PsycINFO re-
lated to medically unexplained physical symptoms.
They found that four functional somatic syndromes
(including IBS) were related to depression and anxiety.
This emotional disturbance would further affect liver
Qi and formed a vicious cycle of effects.
TCM medications based on the liver that are com-
monly used for treating IBS-C are Sini powder, Chai-
hushugan powder, Xiaoyao powder and Tongxieyao
Fang. Sini powder comprises Chaihu (Radix Bupleuri
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Chinensis), Zhishi (Fructus Aurantii Immaturus),
Baishao (Radix Paeoniae Alba) and Gancao (Radix Glyc-
yrrhizae). It is used mainly to treat the stagnation of
Yang as well as Qi stagnation of the liver and spleen.29
Chaihushugan powder is derived from Sini powder in
that Zhishi (Fructus Aurantii Immaturus) is replaced
with Zhiqiao (Fructus Aurantii Submaturus), and Ch-
uanxiong (Rhizoma Chuanxiong), Chenpi (Pericarpium
Citri Reticulatae) and Xiangfu (Rhizoma Cyperi) are
added to enhance the effect of dispersing stagnated liv-
er Qi and promoting blood flow to relieve pain.30
Xiaoyao powder consists of Chaihu (Radix Bupleuri
Chinensis), Danggui (Radix Angelicae Sinensis), Baishao
(Radix Paeoniae Alba), Baizhu (Rhizoma Atractylodis
Macrocephalae), Gancao (Radix Glycyrrhizae), Fuling
(Poria), Bohe (Herba Menthae Haplocalycis) and Paoji-
Figure 2 Difference in efficacy between TCM andWestern Medicine
Figure 3 Difference in cure rate between TCM andWestern Medicine
Figure 4 Difference in efficacy between TCM andWestern Medicine
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ang (Rhizoma Zingiberis Praepararum). It can invigo-
rate the spleen to eliminate dampness. Baizhu (Rhi-
zoma Atractylodis Macrocephalae) and Fuling (Poria)
can regulate the liver, spleen, blood and Qi simultane-
ously.31 Tongxieyaofang is composed of Baizhu (Rhi-
zoma Atractylodis Macrocephalae), Fangfeng (Radix Sa-
poshnikoviae), Chenpi (Pericarpium Citri Reticulatae)
and Baishao (Radix Paeoniae Alba).32 It is a common ba-
sic recipe for treating diarrhea caused by disharmony
between the liver and spleen, and is usually used to
treat IBS-D. However, it has been reported that a com-
bination of Tongxieyaofang and modified Sini powder
can significantly worsen symptoms in patients with
IBS-C or IBS-D.33
Our results provided evidence for the clinical applica-
tion of the TCM theory that "the liver controls convey-
ance, dispersion, stores blood, and is closely connected
to the spleen and stomach". However, the present me-
ta-analysis had limitations. The included studies were
not rigorous; the outcome indicators — efficacy, cure
Figure 5 Difference in recurrence rate between TCM andWestern Medicine
Figure 6 Difference in the incidence of adverse reactions between TCM andWestern Medicine
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rate, and remarkable efficacy — were not consistent.
Hence, the placebo effect could not be ruled out.
In conclusion, the findings derived from the treatment
of IBS-C with TCM based on the liver revealed that
TCM intervention was significantly better than West-
ern Medicine in terms of cure rate, remarkable efficacy,
recurrence rate, and safety. However, because of the
limitations inherited from the studies included in the
analyses, these findings should be viewed with caution.
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